Meeting
2018 ASCO Annual Meeting
A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.
Authors
Niven R. Narain
BERG, LLC, Framingham, MA
Niven R. Narain , Vivek Subbiah , David S. Hong , David Lucius , Viatcheslav R Akmaev , Michael A Kiebish , Gregory M Miller , Eric Milliman , Leonardo O Rodrigues , Lixia Zhang , Rangaprasad Sarangarajan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Conduct of Clinical Research
Clinical Trial Registration Number
NCT01957735
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2541)
DOI
10.1200/JCO.2018.36.15_suppl.2541
Abstract #
2541
Poster Bd #
367
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase I study of BPM 31510 in advanced solid tumors: Omics-based molecular correlation to outcome for patient stratification.
First Author: Manish A. Shah
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu
Poster
2015 ASCO Annual Meeting
Phase 1 study of BPM 31510 (Ubidecarenone) in patients with advanced solid tumors (ST): Use of multiomics platform to evaluate reversal of Warburg effect.
First Author: Ralph Zinner
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam